Abstract
Improving survival has traditionally been the goal of anticancer therapy. Although great strides have been made in cancer therapeutics, it is relatively uncommon that new drugs or biological agents provide substantial improvement in survival. Most of these agents have side effects, some of which are severe, resulting in discomfort and disability. For patients with incurable cancers, overall quality of their remaining life is particularly important. Adequate palliation of cancer-related symptoms, especially pain, may ease suffering and fear, allowing the final journey to be taken with peace and dignity.
This chapter reflects independent work of the authors and does not necessarily represent the view of the Food and Drug Administration.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Transcript of the Quality of Life Subcommittee of the Oncologie Drug Advisory Committee to the Food and Drug Administration, February 10, 2000.
Johnson JR, Williams G, Pazdun R. Endpoints for FDA approval of Oncology Drugs. ASCO abstract #1018, 2002.
World Health Organization. The First Ten Years of the World Health Organization. Geneva: WHO. 1958.
Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med 1996; 334: 835–840.
Osoba D. Lessons learned from measuring health-related quality of life in oncology. J Clin Oncol 1994; 12: 608–616.
Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life-a conceptual model of patient outcomes. JAMA 1995; 273: 59–65.
Beitz J. Quality-of-life endpoints in oncology drug trials. Oncology 1999; 13: 1439–1445.
Aaronson NK. Methodologic issues in assessing the quality of life of cancer patients. Cancer 1991; 67 (3 suppl): 844–850.
Gnecco C, Lachenbruch PA. Regulatory aspects of quality of life. In: Mesbah M, et al., eds. Statistical Methods for Quality of Life Studies, Design, Measurement and Analysis. Dordrecht: Kluwer Academic. 2002.
Beitz J, Gneco C, Justice R. Quality-of-life endpoints in cancer clinical trials: The U.S. Food and Drug Administration Perspective. J Natl Cancer Inst Monogr 1996; 20.
Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998; 16: 139–144.
Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trial 1989; 10: 407–415.
Lydick E, Epstein RS. Interpretation of quality of life changes. Quality Life Res 1993; 2: 221–226.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Chiao, J.H., Williams, G., Griebel, D. (2004). Assessing Tumor-Related Symptoms and Health-Related Quality of Life in Cancer Clinical Trials. In: Teicher, B.A., Andrews, P.A. (eds) Anticancer Drug Development Guide. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-739-0_21
Download citation
DOI: https://doi.org/10.1007/978-1-59259-739-0_21
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4684-9841-7
Online ISBN: 978-1-59259-739-0
eBook Packages: Springer Book Archive